Clinical Trial Update: Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic [Phase 2]

View source ↗

Summary

Phase 2 study of pembrolizumab in patients with rare, unresectable or metastatic solid tumors; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma
• Carcinoma of Unknown Primary
• Cutaneous Squamous Cell Carcinoma
• Germ Cell Tumor
• Paraganglioma
• Penile Cancer
• Pheochromocytoma
• Renal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-18